ReviewHuman mutation2025
Metabolic Reprogramming in Colorectal Cancer: The Impact of Fatty Acid Metabolism.
Review in Human mutation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Prognostic risk modeling based on integrated multi-omics analysis identifies CRY2 as a key regulator in tumor immunity and patient survival in colorectal cancer.Annals of medicine · 2026Article
- Review
- FSCN1 Modulates Fatty Acid Metabolism and the Coordinated Activation of AKT/mTOR and p38 MAPK Pathways in Colorectal Cancer Cells.Oncology research · 2026Article
- Circular RNAs: Key Regulators of Tumor Metabolic Reprogramming and Clinical Translation.Oncology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) ranks among the most common malignant tumors worldwide, with the metabolism of fatty acids being crucial for its development and progression. Altered fatty acid metabolism is a well-established metabolic characteristic of malignant tumors, including CRC. A complex and reciprocal relationship exists between fatty acid metabolism and CRC. On one side, the emergence and advancement of CRC can trigger a reprogramming of fatty acid metabolism. To fulfill the requirements of rapid cell division and survival, cancer cells increase both the synthesis and uptake of fatty acids while also suppressing their oxidation. Conversely, modifications in fatty acid metabolism can affect CRC, as abnormal fatty acid byproducts may activate signaling pathways that foster tumor cell proliferation, thus enhancing tumor progression. Understanding the interplay between fatty acid metabolism and the early stages and advancement of CRC, in conjunction with its relationship with the tumor microenvironment, is a vital area for future investigation. This article reviews the most recent discoveries concerning the impact of fatty acid metabolism on CRC progression, with the objective of supplying a solid theoretical framework and innovative perspectives for additional research and treatment of this condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.